Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei

Clare F. Collett, Carl Kitson, Nicola Baker, Heather B. Steele-Stallard, Marie-Victoire Santrot, Sebastian Hutchinson, David Horn, Sam Alsford (Lead / Corresponding author)

Research output: Contribution to journalArticle

18 Downloads (Pure)

Abstract

The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite Trypanosoma brucei Therefore, we screened our genome-scale T. brucei RNA interference (RNAi) library against the current antileishmanial drugs sodium stibogluconate (antimonial), paromomycin, miltefosine, and amphotericin B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource. Follow-up analyses revealed the antimonial selectivity of the aquaglyceroporin TbAQP3. A lysosomal major facilitator superfamily transporter contributes to paromomycin-aminoglycoside efficacy. The vesicle-associated membrane protein TbVAMP7B and a flippase contribute to amphotericin B and miltefosine action and are potential cross-resistance determinants. Finally, multiple phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania miltefosine transporter, a putative β-subunit/CDC50 cofactor, and additional membrane-associated hits, affect amphotericin B efficacy, providing new insights into mechanisms of drug uptake and action. The findings from this orthology-based chemogenomic profiling approach substantially advance our understanding of antileishmanial drug action and potential resistance mechanisms and should facilitate the development of improved therapies as well as surveillance for drug-resistant parasites.

Original languageEnglish
Article numbere00795-19
Pages (from-to)1-19
Number of pages19
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number8
Early online date3 Jun 2019
DOIs
Publication statusPublished - Aug 2019

Fingerprint

Trypanosoma brucei brucei
miltefosine
Parasites
Pharmaceutical Preparations
Leishmania
Amphotericin B
Paromomycin
Action Potentials
Aquaglyceroporins
Antimony Sodium Gluconate
R-SNARE Proteins
Leishmaniasis
Membrane Transport Proteins
Aminoglycosides
RNA Interference
Libraries
Phospholipids
Cell Membrane
Genome
Membranes

Keywords

  • Leishmania
  • Trypanosoma
  • amphotericin B
  • aquaglyceroporin
  • major facilitator superfamily transporter
  • miltefosine
  • paromomycin
  • phospholipid-transporting ATPase
  • sodium stibogluconate
  • vesicle-associated membrane protein

Cite this

Collett, C. F., Kitson, C., Baker, N., Steele-Stallard, H. B., Santrot, M-V., Hutchinson, S., ... Alsford, S. (2019). Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei. Antimicrobial Agents and Chemotherapy, 63(8), 1-19. [e00795-19]. https://doi.org/10.1128/AAC.00795-19
Collett, Clare F. ; Kitson, Carl ; Baker, Nicola ; Steele-Stallard, Heather B. ; Santrot, Marie-Victoire ; Hutchinson, Sebastian ; Horn, David ; Alsford, Sam. / Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 8. pp. 1-19.
@article{f6977ac73f01417094ff91b072f1e4e5,
title = "Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei",
abstract = "The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite Trypanosoma brucei Therefore, we screened our genome-scale T. brucei RNA interference (RNAi) library against the current antileishmanial drugs sodium stibogluconate (antimonial), paromomycin, miltefosine, and amphotericin B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource. Follow-up analyses revealed the antimonial selectivity of the aquaglyceroporin TbAQP3. A lysosomal major facilitator superfamily transporter contributes to paromomycin-aminoglycoside efficacy. The vesicle-associated membrane protein TbVAMP7B and a flippase contribute to amphotericin B and miltefosine action and are potential cross-resistance determinants. Finally, multiple phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania miltefosine transporter, a putative β-subunit/CDC50 cofactor, and additional membrane-associated hits, affect amphotericin B efficacy, providing new insights into mechanisms of drug uptake and action. The findings from this orthology-based chemogenomic profiling approach substantially advance our understanding of antileishmanial drug action and potential resistance mechanisms and should facilitate the development of improved therapies as well as surveillance for drug-resistant parasites.",
keywords = "Leishmania, Trypanosoma, amphotericin B, aquaglyceroporin, major facilitator superfamily transporter, miltefosine, paromomycin, phospholipid-transporting ATPase, sodium stibogluconate, vesicle-associated membrane protein",
author = "Collett, {Clare F.} and Carl Kitson and Nicola Baker and Steele-Stallard, {Heather B.} and Marie-Victoire Santrot and Sebastian Hutchinson and David Horn and Sam Alsford",
note = "This work was funded by a Wellcome Trust Institutional Strategic Support Fund (LSHTM) fellowship (www.wellcome.ac.uk/) awarded to S.A. D.H. is a Wellcome Trust Investigator award recipient (100320/Z/12/Z). H.B.S.-S. was supported by the Biotechnology and Biological Sciences Research Council (BB/J014567/1).",
year = "2019",
month = "8",
doi = "10.1128/AAC.00795-19",
language = "English",
volume = "63",
pages = "1--19",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

Collett, CF, Kitson, C, Baker, N, Steele-Stallard, HB, Santrot, M-V, Hutchinson, S, Horn, D & Alsford, S 2019, 'Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei', Antimicrobial Agents and Chemotherapy, vol. 63, no. 8, e00795-19, pp. 1-19. https://doi.org/10.1128/AAC.00795-19

Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei. / Collett, Clare F.; Kitson, Carl; Baker, Nicola; Steele-Stallard, Heather B.; Santrot, Marie-Victoire; Hutchinson, Sebastian; Horn, David; Alsford, Sam (Lead / Corresponding author).

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 8, e00795-19, 08.2019, p. 1-19.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemogenomic Profiling of Antileishmanial Efficacy and Resistance in the Related Kinetoplastid Parasite Trypanosoma brucei

AU - Collett, Clare F.

AU - Kitson, Carl

AU - Baker, Nicola

AU - Steele-Stallard, Heather B.

AU - Santrot, Marie-Victoire

AU - Hutchinson, Sebastian

AU - Horn, David

AU - Alsford, Sam

N1 - This work was funded by a Wellcome Trust Institutional Strategic Support Fund (LSHTM) fellowship (www.wellcome.ac.uk/) awarded to S.A. D.H. is a Wellcome Trust Investigator award recipient (100320/Z/12/Z). H.B.S.-S. was supported by the Biotechnology and Biological Sciences Research Council (BB/J014567/1).

PY - 2019/8

Y1 - 2019/8

N2 - The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite Trypanosoma brucei Therefore, we screened our genome-scale T. brucei RNA interference (RNAi) library against the current antileishmanial drugs sodium stibogluconate (antimonial), paromomycin, miltefosine, and amphotericin B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource. Follow-up analyses revealed the antimonial selectivity of the aquaglyceroporin TbAQP3. A lysosomal major facilitator superfamily transporter contributes to paromomycin-aminoglycoside efficacy. The vesicle-associated membrane protein TbVAMP7B and a flippase contribute to amphotericin B and miltefosine action and are potential cross-resistance determinants. Finally, multiple phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania miltefosine transporter, a putative β-subunit/CDC50 cofactor, and additional membrane-associated hits, affect amphotericin B efficacy, providing new insights into mechanisms of drug uptake and action. The findings from this orthology-based chemogenomic profiling approach substantially advance our understanding of antileishmanial drug action and potential resistance mechanisms and should facilitate the development of improved therapies as well as surveillance for drug-resistant parasites.

AB - The arsenal of drugs used to treat leishmaniasis, caused by Leishmania spp., is limited and beset by toxicity and emergent resistance. Furthermore, our understanding of drug mode of action and potential routes to resistance is limited. Forward genetic approaches have revolutionized our understanding of drug mode of action in the related kinetoplastid parasite Trypanosoma brucei Therefore, we screened our genome-scale T. brucei RNA interference (RNAi) library against the current antileishmanial drugs sodium stibogluconate (antimonial), paromomycin, miltefosine, and amphotericin B. Identification of T. brucei orthologues of the known Leishmania antimonial and miltefosine plasma membrane transporters effectively validated our approach, while a cohort of 42 novel drug efficacy determinants provides new insights and serves as a resource. Follow-up analyses revealed the antimonial selectivity of the aquaglyceroporin TbAQP3. A lysosomal major facilitator superfamily transporter contributes to paromomycin-aminoglycoside efficacy. The vesicle-associated membrane protein TbVAMP7B and a flippase contribute to amphotericin B and miltefosine action and are potential cross-resistance determinants. Finally, multiple phospholipid-transporting flippases, including the T. brucei orthologue of the Leishmania miltefosine transporter, a putative β-subunit/CDC50 cofactor, and additional membrane-associated hits, affect amphotericin B efficacy, providing new insights into mechanisms of drug uptake and action. The findings from this orthology-based chemogenomic profiling approach substantially advance our understanding of antileishmanial drug action and potential resistance mechanisms and should facilitate the development of improved therapies as well as surveillance for drug-resistant parasites.

KW - Leishmania

KW - Trypanosoma

KW - amphotericin B

KW - aquaglyceroporin

KW - major facilitator superfamily transporter

KW - miltefosine

KW - paromomycin

KW - phospholipid-transporting ATPase

KW - sodium stibogluconate

KW - vesicle-associated membrane protein

UR - http://www.scopus.com/inward/record.url?scp=85070660612&partnerID=8YFLogxK

U2 - 10.1128/AAC.00795-19

DO - 10.1128/AAC.00795-19

M3 - Article

C2 - 31160283

VL - 63

SP - 1

EP - 19

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00795-19

ER -